Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer (Q33339505)

25 July 2017

title

Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer (English)

1 reference

25 July 2017

1 reference

1 reference

J I Clark

1

1 reference

25 July 2017

K Kancharla

2

1 reference

25 July 2017

R Qamar

3

1 reference

25 July 2017

S Fisher

4

1 reference

25 July 2017

A Hantel

5

1 reference

25 July 2017

J Panganiban

6

1 reference

25 July 2017

L Millbrandt

7

1 reference

25 July 2017

K S Albain

8

1 reference

25 July 2017

language of work or name

1 reference

1 November 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

34

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

271-277

1 reference

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Intensive combined chemotherapy and radiotherapy in patients with nonresectable bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

Tumor-suppressor p53: implications for tumor development and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

An information-intensive approach to the molecular pharmacology of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900251-3

7 January 2021

10.1016/S0169-5002(01)00251-3

Identifiers

DOI

1 reference

25 July 2017

1 reference